This is a list of all the questions and their associated study carrel identifiers. One can learn a lot of the "aboutness" of a text simply by reading the questions.
| identifier | question |
|---|---|
| cord-029882-kufs0fxe | ( SARS- CoV-2) Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-259663-fjvumaby | Hydroxychloroquine causes severe vacuolar myopathy in a patient with chronic graftversus- host disease Antimalarial myopathy: an underdiagnosed complication? |
| cord-262467-epqqd8n8 | Negative nasopharyngeal and oropharyngeal swab does not rule out COVID-19 Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients Middle east respiratory syndrome coronavirus infection dynamics and antibody responses among clinically diverse patients, Saudi Arabia Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome Profiling early humoral response to diagnose novel coronavirus disease( COVID-19) portable tests come online to curb coronavirus pandemic Serology- based tests for COVID-19 Good IgA bad IgG in SARS- CoV-2 infection? |
| cord-257144-3q0un5rl | efficiently suppresses inflammatory responses of human class- switched memory B cells via toll- like receptor 9 inhibition Cutting edge: antimalarial drugs inhibit IFN- b production through blockade of cyclic GMP- AMP synthase- DNA interaction Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory nonsmall- cell lung cancer cells Mechanism of action of Hydroxychloroquine as an Antirheumatic drug Autophagy in immunity and inflammation Inhibition of macroautophagy triggers apoptosis DNA sensing by the cGAS- STING pathway in health and disease Smooth or risky revisit of an old malaria drug for COVID-19? |
| cord-031079-9lxhvyyb | In vitro inhibition of human influenza A virus replication by chloroquine Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Anti- malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-274545-r03g7w0b | ( 2) Was follow- up long enough for outcomes to occur? |
| cord-026811-6bdzut3d | Country& Technical Guidance-Coronavirus disease( COVID-19) Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six- day follow up: a pilot observational study Risk factors associated with acute respiratory distress syndrome and death in patients with corona virus disease 2019 pneumonia in Wuhan, China Compassionate use of remdesivir for patients with severe COVID-19 COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-026811-6bdzut3d | The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta- analysis Meta- analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? |
| cord-270290-i4p4p0o4 | Eye( Lond) Could chloroquine/hydroxychloroquine be harmful in Coronavirus Disease 2019( COVID-19) treatment? |
| cord-275041-fcdwitxy | A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19 Race, socioeconomic deprivation, and hospitalization for COVID-19 in English participants of a national biobank Could chloroquine/hydroxychloroquine be harmful in Coronavirus Disease 2019( COVID-19) treatment? |
| cord-277555-tsd6npma | How should we proceed? |
| cord-253196-et1ekgdl | A rush to judgment? |
| cord-253196-et1ekgdl | What advice should clinicians give to patients with SLE or RA who have difficulty securing HCQ? |
| cord-255690-xc4bxin4 | chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children Mother- tochild transmission of HIV-1: timing and implications for prevention Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-283903-e20v88ge | Should chloroquine and hydroxychloroquine be used to treat COVID-19? |
| cord-262780-ilu5oskk | Bloomberg.com Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non- randomized clinical trial A Rush to Judgment? |
| cord-275037-sji0u8nu | These include bias by indication( why did some patients receive HCQ in addition to standard management, whereas others did not?), a possible immortal time bias( patients who died before treatment administration tend to be included as controls in retrospective studies), and of the fact that residual confounders typically remain even after stringent propensity matching is applied( not all clinically relevant variables are included in or captured by covariate analyses). |
| cord-288311-8kcturbn | ( COVID-19): A Review Benzalkonium Chloride in Albuterol Solutions: Time for a Change? |
| cord-293304-kakxmc14 | Hydroxychloroquine and Chloroquine for Treatment of SARS- CoV-2( COVID-19) New Insights on the Antiviral Effects of Chloroquine against Coronavirus: What to Expect for COVID-19? |
| cord-275340-q8d7rvnj | Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-275340-q8d7rvnj | they effective and safe in rheumatic diseases? |
| cord-281285-5g1rw202 | SARS- CoV-2, ACE2, and hydroxychloroquine: cardiovascular complications, therapeutics, and clinical readouts in the current settings Chloroquine or hydroxychloroquine for COVID-19: is cardiotoxicity a concern? |
| cord-259957-temt8b6f | Could the anti- malarial drug chloroquine treat COVID-19? |
| cord-288017-f9b3t0ts | Understanding immunopathological fallout of human coronavirus infections including COVID‐19: Will they cross the path of rheumatologists? |
| cord-303819-w1785lap | COVID-19 Patients: Experience from Case Series of 54 Patients in Long- Term Care Facilities Composite Outcomes in Randomized Trials: Greater Precision but with Greater Uncertainty? |
| cord-278068-3kg71nf4 | A pilot observational study New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-278068-3kg71nf4 | medRxiv A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19 An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19( COVID-19) Should chloroquine and hydroxychloroquine be used to treat COVID-19? |
| cord-293159-oagv4q1u | The anticancer immune response: indispensable for therapeutic success? |
| cord-286038-a62k3lma | New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-286413-a7wue2e3 | What to expect for COVID-19? |
| cord-267762-mzon01fd | they effective and safe in rheumatic diseases? |
| cord-028530-hpgrbhkl | Antimalarialinduced cardiomyopathy: a systematic review of the literature Cardiovascular complications in patients with COVID-19: consequences of viral toxicities and host immune response Guidance of minimizing risk of druginduced ventricular arrhytmia during treatment of COVID-19: a statement from the Canadian heart rhythm Society Description and proposed management of the acute COVID-19 cardiovascular syndrome COVID-19 and chloroquine/ hydroxychloroquine: is there ophthalmological concern? |
| cord-028530-hpgrbhkl | COVID-19: una ventana de oportunidad? |
| cord-028530-hpgrbhkl | In the absence( pending) of conclusive scientific evidence, what considerations should be taken into account when using HCQ in the treatment of COVID-19? |
| cord-289916-rgvcimk3 | Why add anything to nothing? |
| cord-307570-8f83k2ce | A done and dusted situation? |
| cord-268453-87b298uk | : chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines Avian influenza and sialic acid receptors: more than meets the eye? |
| cord-268453-87b298uk | New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-268453-87b298uk | key: cord-268453- 87b298uk authors: Ibáñez, Sebastián; Martínez, Oriela; Valenzuela, Francisca; Silva, Francisco; Valenzuela, Omar title: Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? |
| cord-285486-99trkti1 | : what is our current state of knowledge? |
| cord-285486-99trkti1 | Pre- existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS Study( APASL COVID-19 Chloroquine as chemoprophylaxis for COVID-19: will this work? |
| cord-326154-01es0zv4 | ( COVID-19) outbreakan update on the status Types and predictors of interferon/ ribavirin induced cardiac complications in the Egyptian patients with chronic hepatitis C virus QTc interval prolongation during favipiravir therapy in an Ebolavirus- infected patient Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? |
| cord-280528-7ivw72l0 | Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it? |
| cord-280528-7ivw72l0 | The Lancet TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis Associations between immune- suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence Treatment outcomes for patients with Middle Eastern respiratory syndrome coronavirus( MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia Safety of Ibuprofen in Patients with COVID-19: causal or confounded? |
| cord-327360-4qpk99x9 | The role of angiotensin- converting enzyme 2 in the pathogenesis of COVID-19: the villain or the hero? |
| cord-327575-5pcnuqgy | A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19 Prevalence of hydroxychloroquine- induced side- effects in dermatology patients: a retrospective survey of 102 patients Ranking self- reported gastrointestinal side effects of pharmacotherapy in sarcoidosis Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand- related issue? |
| cord-293428-8hj06hzt | 2013 Hydroxychloroquine- induced hyperpigmentation in systemic diseases: prevalence, clinical 314 features and risk factors: a cross- sectional study of 41 cases Antimalarials and ophthalmologic safety Updated recommendations on the use of hydroxychloroquine in 317 dermatologic practice Effects of chloroquine on viral 319 infections: an old drug against today's diseases? |
| cord-293428-8hj06hzt | New insights on the antiviral effects of 340 chloroquine against coronavirus: what to expect for COVID-19? |
| cord-293428-8hj06hzt | What Is the Role of COVID-19 Infection in Hypertensive Patients With Diabetes? |
| cord-272419-y3ebt4jm | A suggested new protocol for COVID-19 early management Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Treatment Guidelines Off- label use of medicines for COVID-19 Clinical Management of COVID-19-Interim Guidance Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? |
| cord-272419-y3ebt4jm | COVID-19: A recommendation to examine the effect of hydroxychloroquine in preventing infection and progression New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19? |
| cord-272419-y3ebt4jm | Nowadays, one of the critical issues still to be pointed out regards COVID-19 treatment regimens and timing: which drug, in which phase, for how long? |
| cord-341377-mjdg84ny | medRxiv preprint New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-297010-imciixde | Can you teach old drugs new tricks? |
| cord-297010-imciixde | EUA chloroquine phosphate health care provider fact sheet EUA hydroxychloroquine sulfate health care provider fact sheet Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-297010-imciixde | revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy Chloroquine and hydroxychloroquine binding to melanin: some possible consequences for pathologies Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand- related issue? |
| cord-283064-ncyhvkwl | In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2( SARS- CoV-2) Hydroxychloroquine and azithromycin as a treatment of COVID Hydroxychloroquine for treatment of SARS- CoV-2 infection? |
| cord-283064-ncyhvkwl | vitro How does in vivo biliary elimination of drugs change with age? |
| cord-317561-ewo6vvlr | ( COVID-19) Treatment? |
| cord-317561-ewo6vvlr | New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-339717-2a8zv9xl | to predict QT interval prolongation in hospitalized patients Prolongation of the QTc interval is seen uniformly during early transmural ischemia Who are the long- QT syndrome patients who receive an implantable cardioverter- defibrillator and what happens to them?: |
| cord-347186-tbtmqmpr | The effect of chloroquine on herpesvirus infection in vitro and in vivo Preliminary report of antihepatitis C virus activity of chloroquine and hydroxychloroquine in huh-5- 2 cell line Inhibition of murine RNA tumor virus replication and oncogenesis by chloroquine Inhibition of human immunodeficiency virus infectivity by chloroquine Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine Chloroquine exerts an additive in vitro anti- HIV type 1 associated with didanosine and hydroxyurea Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-318092-errwp80i | SARS- CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century COVID-19: consider cytokine storm syndromes and immunosuppression Immunosuppression for hyperinflammation in COVID-19: a double- edged sword? |
| cord-318092-errwp80i | The Cochrane Collaboration's tool for assessing risk of bias in randomised trials Statistical Primer: heterogeneity, random- or fixed- effects model analyses? |
| cord-340090-dqhdws5k | From Shanghai and U.S. Medical Institutions Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19? |
| cord-324166-6ydn2bvy | A synergistic combination for COVID-19 chemoprophylaxis and treatment? |
| cord-324166-6ydn2bvy | Individualized networkbased drug repositioning infrastructure for precision oncology in the panomics era Drug repurposing: New treatments for zika virus infection? |
| cord-286579-u87lx38h | -how much Is too much? |
| cord-286579-u87lx38h | Are chloroquine and hydroxychloroquine safe prophylactic/ treatment options for SARS- CoV-2( covid-19)? |
| cord-286579-u87lx38h | Chloroquine interference with hemoglobin endocytic trafficking suppresses adaptive heme and iron homeostasis in macrophages: the paradox of an antimalarial agent Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-286579-u87lx38h | Eye( Lond) Antimalarial myopathy: an underdiagnosed complication? |
| cord-332654-nav15g8k | Can we use interleukin-6( IL-6) blockade for coronavirus disease 2019( COVID-19)-induced cytokine release syndrome( CRS)? |
| cord-332654-nav15g8k | hsa- miR-25- 3p suppresses the expression and drug induction of CYP2B6 in human hepatocytes Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review Impact of OATP transporters on pharmacokinetics Phagocytosis of retinal rod and cone photoreceptors Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? |
| cord-341101-5yvjbr5q | A new virus isolated from the human respiratory tract Identification of a new human coronavirus Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia Coronavirus as a possible cause of severe acute respiratory syndrome Identification of a novel coronavirus in patients with severe acute respiratory syndrome Koch's postulates fulfilled for SARS virus Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia A Novel Coronavirus from Patients with Pneumonia in China Severe acute respiratory syndrome- related coronavirus: The species and its viruses-a statement of the Coronavirus Study Group Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle Drug treatment options for the 2019-new coronavirus( 2019-nCoV) Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression Comparison of the antiviral activity in vitro of some non- steroidal antiinflammatory drugs Antihistaminics, local anesthetics, and other amines as antiviral agents Effect of chloroquine on the growth of animal viruses Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-341101-5yvjbr5q | Focus on recent advancements Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases Melanin: blackguard or red herring? |
| cord-316992-fe5u2oi0 | Elevated golgi pH impairs terminal N- glycosylation by inducing mislocalization of golgi glycosyltransferases Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review Cytokines as therapeutic targets in SLE Chloroquine cardiotoxicity: clinicopathologic features in three patients and comparison with three patients with Fabry disease Chloroquine retinopathy in the rhesus monkey Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review A review of controlled clinical trials examining the effects of antimalarial compounds and gold compounds on radiographic progression in rheumatoid arthritis Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-316992-fe5u2oi0 | Nurr1 modulation versus autophagy inhibition Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? |
| cord-316992-fe5u2oi0 | a lysosomal degradation pathway with a central role in health and disease Pro- inflammatory Ca++-activated K+ channels are inhibited by hydroxychloroquine Antiviral activity of chloroquine against dengue virus type 2 replication in aotus monkeys Anti- TNFa therapy of rheumatoid arthritis: what have we learned? |
| cord-317761-tkqmu1va | Avian influenza and sialic acid receptors: more than meets the eye? |
| cord-317761-tkqmu1va | New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-317761-tkqmu1va | The use of chloroquine and hydroxychloroquine for non- infectious conditions other than rheumatoid arthritis or lupus: a critical review Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-295144-tyyc81uc | A cross- sectional study on 916 atients Are patients with systemic lupus erythematosus at increased risk for COVID-19? |
| cord-295144-tyyc81uc | COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy versus apremilast in North Spain COVID-19 with rheumatic diseases: a report of 5 cases Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? |
| cord-295144-tyyc81uc | a multicenter prospective cohort study Prevalence, specificity, and clinical association of anti- phospholipid antibodies in COVID-19 patients: are the antibodies really guilty? |
| cord-295144-tyyc81uc | the risk of a complicated course of CTD/ vasculitis patients heightened? |
| cord-328257-kl4wh2zg | Alzheimer's disease and cytokine IL-10 gene polymorphisms: is there an association? |
| cord-328257-kl4wh2zg | Monaldi Arch Chest Dis Hydroxychloroquine in rheumatic autoimmune disorders and beyond Rethinking the role of hydroxychloroquine in the treatment of COVID-19 Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS- CoV-2 infection Chloroquine psychosis: a chemical psychosis? |
| cord-328257-kl4wh2zg | The role of the innate immune system in psychiatric disorders Inflammation in psychiatric disorders: what comes first? |
| cord-342746-2hbcbvt6 | An old drug against today's diseases? |
| cord-342746-2hbcbvt6 | Confronting an influenza pandemic with inexpensive generic agents: can it be done? |
| cord-342746-2hbcbvt6 | New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-312875-gn6hg6oc | A Statement from the Canadian Heart Rhythm Society Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society Is the type of diabetes treatment relevant to outcome of COVID-19? |
| cord-312875-gn6hg6oc | A new job for an old drug? |
| cord-312875-gn6hg6oc | Hydroxychloroquine improves insulin sensitivity in obese non- diabetic individuals Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-312875-gn6hg6oc | Hydroxychloroquine neuromyotoxicity Hydroxychloroquine causes severe vacuolar myopathy in a patient with chronic graft- versus- host disease Antimalarial myopathy: an underdiagnosed complication? |
| cord-347775-hidb8q1u | Hydroxychloroquine for treatment of SARS- CoV-2 infection? |
| cord-347775-hidb8q1u | we all in this together? |
| cord-268425-xg8xnjf9 | Adenosine regulates the proinflammatory signaling function of thrombin in endothelial cells Bench- to- bedside review: adenosine receptors-- promising targets in acute lung injury? |
| cord-268425-xg8xnjf9 | Beta Glucan: Supplement or Drug? |
| cord-268425-xg8xnjf9 | Does vitamin D status impact mortality from SARS- CoV-2 infection? |
| cord-268425-xg8xnjf9 | Hypomagnesemia Impact on the Outcome of Patients Admitted to the Intensive Care Unit? |
| cord-306351-ka6asw3m | ( COVID-19): A Review A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19 Arbidol combined with LPV/ r versus LPV/ r alone against Corona Virus Disease 2019: A retrospective cohort study Baricitinib for COVID-19: a suitable treatment? |
| cord-306351-ka6asw3m | How will country- based mitigation measures influence the course of the COVID-19 epidemic? |
| cord-306351-ka6asw3m | Hydroxychloroquine in Covid-19: Does the end justify the means? |
| cord-306351-ka6asw3m | Is Blocked by a Clinically Proven Protease Inhibitor Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? |
| cord-333144-gyuh2fvl | An alternative drug for the treatment of COVID-19? |
| cord-333144-gyuh2fvl | Another zoonotic betacoronavirus causing SARS- like disease Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: Trends, scope and relevance Doxycycline, a widely used antibiotic in dermatology with a possible anti- inflammatory action against IL-6 in COVID-19 outbreak MERS- CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte- derived antigen- presenting cells Favipiravir, an antiviral for COVID-19? |
| cord-333144-gyuh2fvl | The COVID-19 vaccine development landscape Dexamethasone for COVID-19? |
| cord-333144-gyuh2fvl | What is new on its pathogenesis and complications? |
| cord-351510-8m4930bc | A randomized controlled trial In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2( SARS- CoV-2) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non- randomized clinical trial A rush to judgment? |
| cord-351510-8m4930bc | But what counts as scientific and/or sufficient evidence? |
| cord-351510-8m4930bc | Is France's president fueling the hype over an unproven coronavirus treatment? |
| cord-351510-8m4930bc | The ethics of consent: theory and practice Expanding the frame of"voluntariness"in informed consent: structural coercion and the power of social and economic context Consent to clinical research-- adequately voluntary or substantially influenced? |
| cord-353749-2vlc11rx | A randomized clinical trial Hydroxychloroquine as pre- exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial Beyond the randomized controlled trial: a review of alternatives in mHealth clinical trial methods Effect of a US National Institutes of Health programme of clinical trials on public health and costs Characteristics and strength of evidence of COVID-19 studies registered on ClinicalTrials.gov COVID-19: real- time dissemination of scientific information to fight a public health emergency of international concern Mefloquine at the crossroads? |
| cord-353749-2vlc11rx | A randomized clinical trial Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19 Potent neutralizing antibodies directed to multiple epitopes on SARS- CoV-2 spike Antibody therapies could be a bridge to a coronavirus vaccine-but will the world benefit? |
| cord-353749-2vlc11rx | Where can we find a prophylactic treatment that is easy to use, inexpensive and already available? |
| cord-327006-m847xdzk | Do Blood Concentrations Matter? |
| cord-327006-m847xdzk | Does mortality rate of a population or the severity of the disease affect HCQ efficacy? |
| cord-327006-m847xdzk | However, a number of questions remain open on the relationship between HCQ treatments in COVID-19 patients: is there a dose issue? |
| cord-327006-m847xdzk | Is there any interaction with other anti- COVID19 drugs? |
| cord-327006-m847xdzk | The possible mechanisms of action of 4-aminoquinolines( chloroquine/ hydroxychloroquine) against Sars- Cov-2 infection( COVID-19): A role for iron homeostasis? |
| cord-327006-m847xdzk | medRxiv preprint Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-350992-l6l24pco | : Is Ferritinophagy the Link? |
| cord-350992-l6l24pco | New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-350992-l6l24pco | The authors declare the following financial interests/ personal relationships which may be considered as Of chloroquine and COVID-19 Viral infection and iron metabolism Hepcidin and the iron- infection axis Iron and infection Guidelines for the use and interpretation of assays for monitoring autophagy Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-350992-l6l24pco | The possible mechanisms of action of 4-aminoquinolines( chloroquine/ hydroxychloroquine) against Sars- Cov-2 infection( COVID-19): A role for iron homeostasis? |
| cord-350992-l6l24pco | Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis? |
| cord-323647-q67fa0m3 | A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19( COVID-19) A case of breakthrough COVID-19 during hydroxychloroquine maintenance Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19 Usefulness of hydroxychloroquine for COVID-19: does answer lie in timing to start? |
| cord-323647-q67fa0m3 | COVID-19 and hydroxychloroquine: is the wonder drug failing? |
| cord-323647-q67fa0m3 | Can the thiol/ disulfide imbalance be a predictor of colchicine resistance in familial mediterranean fever? |
| cord-323647-q67fa0m3 | The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition The marketing of unproven drugs for diabetes and dyslipidaemia in India Hydroxychloroquine, a promising choice for coronary artery disease? |
| cord-323647-q67fa0m3 | When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients? |
| cord-352557-l7sahv5t | A first step in understanding SARS pathogenesis Temporal dynamics in viral shedding and transmissibility of COVID-19 Appraising the evidence: What is selection bias? |
| cord-352557-l7sahv5t | In line with the PICOT format( Riva et al., 2012) of framing subjects for clinical research, this study centres on answering the question:'In patients suspected of, and diagnosed with, COVID-19, How efficacious, relative to standard symptomatic care, and safe are CQ and HCQ in patients at risk or suspected of, and diagnosed with, COVID-19?' |
| cord-352557-l7sahv5t | What Clinicians Should Know about the QT Interval Chloroquine and COVID-19: A Light at the End of the Tunnel, or is it Another Train? |
| cord-352557-l7sahv5t | What is your research question? |
| cord-026340-2nf97zvc | : what to expect for COVID-19? |
| cord-026340-2nf97zvc | Does CQ have anti- viral effects? |
| cord-026340-2nf97zvc | How did COVID-19 originate? |
| cord-026340-2nf97zvc | How does CQ help eliminate malarial parasite? |
| cord-026340-2nf97zvc | How effective can be CQ against SARS? |
| cord-026340-2nf97zvc | How long has it been since we know chloroquine( CQ, 9-aminoquinoline)? |
| cord-026340-2nf97zvc | PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer Inhibition of betulinic acid to growth and angiogenesis of human colorectal cancer cell in nude mice Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-026340-2nf97zvc | What are the possible ways SARS- CoV2 infect a host cell? |
| cord-026340-2nf97zvc | What are the symptoms of COVID-19? |
| cord-026340-2nf97zvc | What governs the affinity of a virus towards the human host cell? |
| cord-026340-2nf97zvc | What is COVID-19? |
| cord-315598-qwh72inx | A Missing Link? |
| cord-315598-qwh72inx | Ann Intensive Care Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta- analysis Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome and Posterior Probability of Mortality Benefit in a Post Hoc Bayesian Analysis of a Randomized Clinical Trial Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis- Associated Organ Dysfunction in Children Use of ECMO in ARDS: does the EOLIA trial really help? |
| cord-315598-qwh72inx | COVID-19 pneumonia: ARDS or not? |
| cord-315598-qwh72inx | COVID-19 pneumonia: different respiratory treatment for different phenotypes? |
| cord-315598-qwh72inx | Can Lung US Help Critical Care Clinicians in the Early Diagnosis of Novel Coronavirus( COVID-19) Pneumonia? |
| cord-315598-qwh72inx | Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients? |
| cord-315598-qwh72inx | Cómo podemos medir la calidad de vida, en los pacientes con COVID-19 que egresan de la uci? |
| cord-315598-qwh72inx | Documento de Rionegro Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019( COVID-19) COVID-19 pneumonia: different respiratory treatments for different phenotypes? |
| cord-315598-qwh72inx | Does COVID19 Infect the Brain? |
| cord-315598-qwh72inx | Does SARS- Cov-2 invade the brain? |
| cord-315598-qwh72inx | Does central venous pressure predict fluid responsiveness? |
| cord-315598-qwh72inx | Heart Lung Patient selfproning with high- flow nasal cannula improves oxygenation in COVID-19 pneumonia Expert Recommendations for Tracheal Intubation in Critically ill Patients with Noval Coronavirus Disease Intubation and Ventilation amid the COVID-19 Outbreak: Wuhan's Experience Sedation for critically ill patients with COVID-19: Which specificities? |
| cord-315598-qwh72inx | How should health systems prepare for the evolving COVID-19 pandemic? |
| cord-315598-qwh72inx | How will countrybased mitigation measures influence the course of the COVID-19 epidemic? |
| cord-315598-qwh72inx | Incidence, clinical course, and outcome in 217 patients with acute respiratory distress syndrome Driving pressure and survival in the acute respiratory distress syndrome Driving pressure: a marker of severity, a safety limit, or a goal for mechanical ventilation? |
| cord-315598-qwh72inx | Management of COVID-19 Respiratory Distress Stages or phenotypes? |
| cord-315598-qwh72inx | Noninvasive ventilation in acute cardiogenic pulmonary edema Noninvasive Ventilation in Acute Heart Failure Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure Is there a role for noninvasive ventilation in acute respiratory distress syndrome? |
| cord-315598-qwh72inx | Pautas COVID-19 HiSpaFlow) endGEMdTdScAFeA. Respiratory support therapy after extubation: Who and how? |
| cord-315598-qwh72inx | Pdlr An international survey of training in adult intensive care medicine Do intensivist staffing patterns influence hospital mortality following ICU admission? |
| cord-315598-qwh72inx | Por qué seguimos buscando métodos alternativos? |
| cord-315598-qwh72inx | Radiography( Lond) Point- of- Care Lung Ultrasound Findings in Patients with COVID-19 Pneumonia Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic D- dimer in patients infected with COVID-19 and suspected pulmonary embolism Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Anticoagulation in COVID-19 Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta- analysis Procalcitonin in patients with severe coronavirus disease 2019( COVID-19): A meta- analysis Viral load of SARS- CoV-2 in clinical samples Discharge criteria for confirmed COVID-19 cases-When is it safe to discharge COVID-19 cases from the hospital or end home isolation? |
| cord-315598-qwh72inx | The SARS, MERS and novel coronavirus( COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? |
| cord-315598-qwh72inx | Underestimated Opportunistic Pathogens of the Central Nervous System? |
| cord-315598-qwh72inx | What are the effects of multimodal campaigns to improve hand hygiene of healthcare workers? |
| cord-315598-qwh72inx | Will This Hemodynamically Unstable Patient Respond to a Bolus of Intravenous Fluids? |
| cord-315598-qwh72inx | a la bata manga larga con antifluido durante la atención del paciente con COVID-19? |
| cord-315598-qwh72inx | beneficios en desenlaces clínicos de interés? |
| cord-315598-qwh72inx | convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? |
| cord-315598-qwh72inx | de COVID-19? |
| cord-315598-qwh72inx | why, when and how? |